The study of surveillance in breast cancer with germline TP53 mutation

TP53 germline mutation testing in breast cancer - The study of surveillance in breast cancer with germline TP53 mutation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000042155

Enrollment

Registered

2020-10-30

Start date

2021-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary breast cancer with germline TP53 mutation

Interventions

Biochemical and imaging surveillance in breast cancer with TP53 germline mutation after treatment of breast cancer for 10 years

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Breast cancer patients examined for TP53 germline testing

Exclusion criteria

Exclusion criteria: Breast cancer patients evaluated not to be appropriate for this study by the reseacher in charge

Design outcomes

Primary

Measure	Time frame
The detection of asymptomatic malignant tumours relevant to Li-Fraumeni syndrome after the treatment of breast cancer for 10 years	—

Countries

Japan

Contacts

Public ContactHiroyuki Maeda

Faculty of medicine, University of Fukui First Department of Surgery

maedah@u-fukui.ac.jp0776613111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026